<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2025-285</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-9319</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕВМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RHEUMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Доклинический ревматоидный артрит: современный взгляд на патогенез и возможности профилактики</article-title><trans-title-group xml:lang="en"><trans-title>Preclinical rheumatoid arthritis: A modern view of the pathogenesis and possibilities of prevention</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1833-5357</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аронова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Aronova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аронова Евгения Сергеевна - к.м.н., научный сотрудник лаборатории коморбидных инфекций и вакцинопрофилактики.</p><p>115522, Москва, Каширское шоссе, д. 34А</p></bio><bio xml:lang="en"><p>Evgeniya S. Aronova - Cand. Sci. (Med.), Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention.</p><p>34А, Kashirskoe Shosse, Moscow, 115522</p></bio><email xlink:type="simple">eugpozd@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7091-2054</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белов</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белов Борис Сергеевич - д.м.н., профессор, заведующий лабораторией коморбидных инфекций и вакцинопрофилактики, Научноисследовательский институт ревматологии имени В.А. Насоновой.</p><p>115522, Москва, Каширское шоссе, д. 34А</p></bio><bio xml:lang="en"><p>Boris S. Belov - Dr. Sci. (Med.), Head of the Laboratory of Comorbid Infections and Vaccine Prevention.</p><p>34А, Kashirskoe Shosse, Moscow, 115522</p></bio><email xlink:type="simple">belovbor@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0928-3911</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гриднева</surname><given-names>Г. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gridneva</surname><given-names>G. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гриднева Галина Игоревна - к.м.н., научный сотрудник лаборатории коморбидных инфекций и вакцинопрофилактики.</p><p>115522, Москва, Каширское шоссе, д. 34А</p></bio><bio xml:lang="en"><p>Galina I. Gridneva - Cand. Sci. (Med.), Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention.</p><p>34А, Kashirskoe Shosse, Moscow, 115522</p></bio><email xlink:type="simple">gigridneva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научно-исследовательский институт ревматологии имени В.А. Насоновой<country>Россия</country></aff><aff xml:lang="en">Nasonova Research Institute of Rheumatology<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>08</month><year>2025</year></pub-date><volume>0</volume><issue>12</issue><fpage>172</fpage><lpage>181</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аронова Е.С., Белов Б.С., Гриднева Г.И., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Аронова Е.С., Белов Б.С., Гриднева Г.И.</copyright-holder><copyright-holder xml:lang="en">Aronova E.S., Belov B.S., Gridneva G.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/9319">https://www.med-sovet.pro/jour/article/view/9319</self-uri><abstract><p>Ревматоидный артрит (РА) представляет собой хроническое аутоиммунное заболевание с многофакторной патогенетической основой, характеризующееся прогрессивным развитием, предшествующим клиническим проявлениям. Рассмотрена естественная история заболевания, включающая этапы от генетической предрасположенности и воздействия внешних провоцирующих факторов до формирования доклинического аутоиммунитета и последующего воспалительного поражения суставов. Центральную роль в патогенезе играет взаимодействие ключевых генетических детерминант, таких как аллели HLA-DRB1, с экзогенными триггерами, включая курение и инфекционные факторы, приводящее к продукции специфических аутоантител – антицитруллинированных белковых антител и ревматоидного фактора. Эти серологические маркеры могут регистрироваться за годы до появления суставных симптомов, что указывает на длительный доклинический период заболевания. Продромальные этапы РА, сопровождающиеся системным воспалением и иммунной дисрегуляцией, рассматриваются как критические «окна возможностей» для профилактических мероприятий, направленных на предотвращение перехода заболевания в клинически выраженную фазу. Особую важность приобретают исследования, направленные на восстановление иммунологической толерантности и модуляцию микробиома, что открывает перспективы для разработки инновационных терапевтических подходов. Они должны быть ориентированы на предотвращение заболевания на самых ранних этапах его патогенеза, задолго до появления клинических признаков. Кроме того, разработка методов визуализации субклинических изменений и уточнение критериев стратификации риска станут критически важными для идентификации лиц, нуждающихся в целенаправленном воздействии. Современные принципы первичной и вторичной профилактики включают модификацию факторов риска (отказ от курения табака, коррекцию микробиома и диеты). Эти подходы открывают перспективы для снижения заболеваемости РА среди лиц с генетической предрасположенностью или наличием иммунологических маркеров на доклинической стадии заболевания.</p></abstract><trans-abstract xml:lang="en"><p>Rheumatoid arthritis (RA) is a chronic autoimmune disease with a multifactorial pathogenetic basis, characterized by progressive development preceding clinical manifestation. This review examines the natural history of the disease, including stages from genetic predisposition and exposure to external provoking factors to the formation of preclinical autoimmunity and subsequent inflammatory joint damage. The central role in pathogenesis is played by the interaction of key genetic determinants, such as HLA-DRB1 alleles, with exogenous triggers, including smoking and infectious agents, leading to the production of specific autoantibodies – anticitrullinated protein antibodies and rheumatoid factor. These serological markers can be recorded years before the onset of joint symptoms, indicating a long preclinical period of the disease. Prodromal stages of RA, accompanied by systemic inflammation and immune dysregulation, are considered as critical “windows of opportunity” for preventive measures aimed at preventing the disease from progressing to a clinically expressed phase. Of particular importance are studies aimed at restoring immunological tolerance and modulating microbiomes, which opens up prospects for the development of innovative therapeutic approaches. These strategies should be aimed at preventing disease at the earliest stages of its pathogenesis, long before clinical manifestation. In addition, the development of methods for visualizing subclinical changes and refining risk stratification criteria will be critical for identifying individuals in need of targeted measures. Current strategies of primary and secondary prevention include risk factor modification (smoking cessation, microbiome and diet correction). These approaches offer prospects for reducing the incidence of RA among individuals with a genetic predisposition or the presence of immunological markers in the preclinical stage of the disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит без клинических проявлений</kwd><kwd>цитокины</kwd><kwd>антитела к цитруллинированному пептиду</kwd><kwd>курение</kwd><kwd>магнитно-резонансная томография</kwd><kwd>микробиота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>preclinical rheumatoid arthritis</kwd><kwd>cytokines</kwd><kwd>citrullinated peptide antibodies</kwd><kwd>smoking</kwd><kwd>magnetic resonance imaging</kwd><kwd>gut microbiota</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Статья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», номер государственного задания РК 125020301268-4</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>This article has been prepared as part of the research work of Nasonova Research Institute of Reumatology under RK State Assignment No. 125020301268-4</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591–602. https://doi.org/10.1038/s41584-022-00827-y.</mixed-citation><mixed-citation xml:lang="en">Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591–602. https://doi.org/10.1038/s41584-022-00827-y.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71(5):638–641. https://doi.org/10.1136/annrheumdis-2011-200990.</mixed-citation><mixed-citation xml:lang="en">Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71(5):638–641. https://doi.org/10.1136/annrheumdis-2011-200990.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Frisell T, Holmqvist M, Källberg H, Klareskog L, Alfredsson L, Asklingj. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum. 2013;65(11):2773–2782. https://doi.org/10.1002/art.38097.</mixed-citation><mixed-citation xml:lang="en">Frisell T, Holmqvist M, Källberg H, Klareskog L, Alfredsson L, Asklingj. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum. 2013;65(11):2773–2782. https://doi.org/10.1002/art.38097.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–381. https://doi.org/10.1038/nature12873.</mixed-citation><mixed-citation xml:lang="en">Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–381. https://doi.org/10.1038/nature12873.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum. 2004;50(2):400–412. https://doi.org/10.1002/art.20006.</mixed-citation><mixed-citation xml:lang="en">Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum. 2004;50(2):400–412. https://doi.org/10.1002/art.20006.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015;313(16):1645–1656. https://doi.org/10.1001/jama.2015.3435.</mixed-citation><mixed-citation xml:lang="en">Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015;313(16):1645–1656. https://doi.org/10.1001/jama.2015.3435.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">van der Woude D, Lie BA, Lundström E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ et al. Protection against anti-citrullinated protein antibodypositive rheumatoid arthritis is predominantly associated with HLADRB1*1301: a meta-analysis of HLA-DRB1 associations with anticitrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 2010;62(5):1236–1245. https://doi.org/10.1002/art.27366.</mixed-citation><mixed-citation xml:lang="en">van der Woude D, Lie BA, Lundström E, Balsa A, Feitsma AL, HouwingDuistermaat JJ et al. Protection against anti-citrullinated protein antibodypositive rheumatoid arthritis is predominantly associated with HLADRB1*1301: a meta-analysis of HLA-DRB1 associations with anticitrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 2010;62(5):1236–1245. https://doi.org/10.1002/art.27366.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75(3):330–337. https://doi.org/10.1086/422827.</mixed-citation><mixed-citation xml:lang="en">Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75(3):330–337. https://doi.org/10.1086/422827.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B et al. TRAF1-C5 as a risk locus for rheumatoid arthritis – a genome-wide study. N Engl J Med. 2007;357(12):1199–1209. https://doi.org/10.1056/NEJMoa073491.</mixed-citation><mixed-citation xml:lang="en">Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B et al. TRAF1-C5 as a risk locus for rheumatoid arthritis – a genome-wide study. N Engl J Med. 2007;357(12):1199–1209. https://doi.org/10.1056/NEJMoa073491.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977–986. https://doi.org/10.1056/NEJMoa073003.</mixed-citation><mixed-citation xml:lang="en">Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977–986. https://doi.org/10.1056/NEJMoa073003.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K et al. Multiancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat Genet. 2022;54(11):1640–1651. https://doi.org/10.1038/s41588-022-01213-w.</mixed-citation><mixed-citation xml:lang="en">Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K et al. Multiancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat Genet. 2022;54(11):1640–1651. https://doi.org/10.1038/s41588-022-01213-w.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Webster AP, Plant D, Ecker S, Zufferey F, Bell JT, Feber A et al. Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins. Genome Med. 2018;10(1):64. https://doi.org/10.1186/s13073018-0575-9.</mixed-citation><mixed-citation xml:lang="en">Webster AP, Plant D, Ecker S, Zufferey F, Bell JT, Feber A et al. Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins. Genome Med. 2018;10(1):64. https://doi.org/10.1186/s13073018-0575-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">de Andres MC, Perez-Pampin E, Calaza M, Santaclara FJ, Ortea I, Gomez-Reino JJ, Gonzalez A. Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. Arthritis Res Ther. 2015;17(1):233. Available at: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075015-0748-5.</mixed-citation><mixed-citation xml:lang="en">de Andres MC, Perez-Pampin E, Calaza M, Santaclara FJ, Ortea I, GomezReino JJ, Gonzalez A. Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. Arthritis Res Ther. 2015;17(1):233. Available at: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075015-0748-5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46. https://doi.org/10.1002/art.21575.</mixed-citation><mixed-citation xml:lang="en">Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46. https://doi.org/10.1002/art.21575.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kim K, Jiang X, Cui J, Lu B, Costenbader KH, Sparks JA et al. Interactions between amino acid-defined major histocompatibility complex class II variants and smoking in seropositive rheumatoid arthritis. Arthritis Rheumatol. 2015;67(10):2611–2623. https://doi.org/10.1002/art.39228.</mixed-citation><mixed-citation xml:lang="en">Kim K, Jiang X, Cui J, Lu B, Costenbader KH, Sparks JA et al. Interactions between amino acid-defined major histocompatibility complex class II variants and smoking in seropositive rheumatoid arthritis. Arthritis Rheumatol. 2015;67(10):2611–2623. https://doi.org/10.1002/art.39228.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther. 2015;17(1):86. https://doi.org/10.1186/s13075-015-0601-x.</mixed-citation><mixed-citation xml:lang="en">Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther. 2015;17(1):86. https://doi.org/10.1186/s13075-015-0601-x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gan RW, Bemis EA, Demoruelle MK, Striebich CC, Brake S, Feser ML et al. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. Rheumatology. 2017;56(12):2229–2236. https://doi.org/10.1093/rheumatology/kex360.</mixed-citation><mixed-citation xml:lang="en">Gan RW, Bemis EA, Demoruelle MK, Striebich CC, Brake S, Feser ML et al. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. Rheumatology. 2017;56(12):2229–2236. https://doi.org/10.1093/rheumatology/kex360.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Alpizar-Rodriguez D, Mueller RB, Möller B, Dudler J, Ciurea A, Zufferey P et al. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology. 2017;56(9):1579–1585. https://doi.org/10.1093/rheumatology/kex239.</mixed-citation><mixed-citation xml:lang="en">Alpizar-Rodriguez D, Mueller RB, Möller B, Dudler J, Ciurea A, Zufferey P et al. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology. 2017;56(9):1579–1585. https://doi.org/10.1093/rheumatology/kex239.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kudaeva FM, Speechley MR, Pope JE. A systematic review of viral exposures as a risk for rheumatoid arthritis. Semin Arthritis Rheum. 2019;48(4):587–596. https://doi.org/10.1016/j.semarthrit.2018.03.011.</mixed-citation><mixed-citation xml:lang="en">Kudaeva FM, Speechley MR, Pope JE. A systematic review of viral exposures as a risk for rheumatoid arthritis. Semin Arthritis Rheum. 2019;48(4):587–596. https://doi.org/10.1016/j.semarthrit.2018.03.011.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ono K, Kishimoto M, Shimasaki T, Uchida H, Kurai D, Deshpande GA et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020;6(2):e001350. https://doi.org/10.1136/rmdopen-2020-001350.</mixed-citation><mixed-citation xml:lang="en">Ono K, Kishimoto M, Shimasaki T, Uchida H, Kurai D, Deshpande GA et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020;6(2):e001350. https://doi.org/10.1136/rmdopen-2020-001350.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Аронова ЕС, Белов БС. Полиартрит, ассоциированный с COVID-19 (клинический случай). Современная ревматология. 2021;15(1):76–79. https://doi.org/10.14412/1996-7012-2021-5-76-79.</mixed-citation><mixed-citation xml:lang="en">Aronova ES, Belov BS. Polyarthritis associated with COVID-19 (clinical case). Sovremennaya Revmatologiya. 2021;15(5):76–79. (In Russ.) https://doi.org/10.14412/1996-7012-2021-5-76-79.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Joo YB, Lee J, Park YJ, Bang SY, Kim K, Lee HS. Associations of upper respiratory mucosa microbiota with rheumatoid arthritis, autoantibodies, and disease activity. PLoS ONE. 2024;19(1):e0308010. https://doi.org/10.1371/journal.pone.0308010.</mixed-citation><mixed-citation xml:lang="en">Joo YB, Lee J, Park YJ, Bang SY, Kim K, Lee HS. Associations of upper respiratory mucosa microbiota with rheumatoid arthritis, autoantibodies, and disease activity. PLoS ONE. 2024;19(1):e0308010. https://doi.org/10.1371/journal.pone.0308010.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, Venables PJ. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233(1):34–54. https://doi.org/10.1111/j.0105-2896.2009.00850.x.</mixed-citation><mixed-citation xml:lang="en">Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, Venables PJ. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233(1):34–54. https://doi.org/10.1111/j.0105-2896.2009.00850.x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488–1492. https://doi.org/10.1136/ard.2007.075192.</mixed-citation><mixed-citation xml:lang="en">Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488–1492. https://doi.org/10.1136/ard.2007.075192.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Johansson L, Sherina N, Kharlamova N, Potempa B, Larsson B, Israelsson L et al. Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):201. https://doi.org/10.1186/s13075-016-1100-4.</mixed-citation><mixed-citation xml:lang="en">Johansson L, Sherina N, Kharlamova N, Potempa B, Larsson B, Israelsson L et al. Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):201. https://doi.org/10.1186/s13075-016-1100-4.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Tong Y, Zheng L, Qing P, Zhao H, Li Y, Su L et al. Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis. Front Cell Infect Microbiol. 2020;9:475. https://doi.org/10.3389/fcimb.2019.00475.</mixed-citation><mixed-citation xml:lang="en">Tong Y, Zheng L, Qing P, Zhao H, Li Y, Su L et al. Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis. Front Cell Infect Microbiol. 2020;9:475. https://doi.org/10.3389/fcimb.2019.00475.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Jubair WK, Hendrickson JD, Severs EL, Schulz HM, Adhikari S, Ir D et al. Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal Inflammation and Autoantibody Generation. Arthritis Rheumatol. 2018;70(8):1220–1233. https://doi.org/10.1002/art.40490.</mixed-citation><mixed-citation xml:lang="en">Jubair WK, Hendrickson JD, Severs EL, Schulz HM, Adhikari S, Ir D et al. Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal Inflammation and Autoantibody Generation. Arthritis Rheumatol. 2018;70(8):1220–1233. https://doi.org/10.1002/art.40490.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Chen B, Sun L, Zhang X. Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases. J Autoimmun. 2017;83:31–42. https://doi.org/10.1016/j.jaut.2017.03.009.</mixed-citation><mixed-citation xml:lang="en">Chen B, Sun L, Zhang X. Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases. J Autoimmun. 2017;83:31–42. https://doi.org/10.1016/j.jaut.2017.03.009.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Luo Y, Tong Y, Wu L, Niu H, Li Y, Su LC et al. Alteration of Gut Microbiota in Individuals at High-Risk for Rheumatoid Arthritis Associated With Disturbed Metabolome and the Initiation of Arthritis Through the Triggering of Mucosal Immunity Imbalance. Arthritis Rheumatol. 2023;75(10):1736–1748. https://doi.org/10.1002/art.42616.</mixed-citation><mixed-citation xml:lang="en">Luo Y, Tong Y, Wu L, Niu H, Li Y, Su LC et al. Alteration of Gut Microbiota in Individuals at High-Risk for Rheumatoid Arthritis Associated With Disturbed Metabolome and the Initiation of Arthritis Through the Triggering of Mucosal Immunity Imbalance. Arthritis Rheumatol. 2023;75(10):1736–1748. https://doi.org/10.1002/art.42616.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Seifert JA, Bemis EA, Ramsden K, Lowell C, Polinski K, Feser M et al. Association of Antibodies to Prevotella copri in Anti-Cyclic Citrullinated Peptide-Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis. Arthritis Rheumatol. 2023;75(4):507–516. https://doi.org/10.1002/art.42370.</mixed-citation><mixed-citation xml:lang="en">Seifert JA, Bemis EA, Ramsden K, Lowell C, Polinski K, Feser M et al. Association of Antibodies to Prevotella copri in Anti-Cyclic Citrullinated Peptide-Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis. Arthritis Rheumatol. 2023;75(4):507–516. https://doi.org/10.1002/art.42370.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8(1):43. https://doi.org/10.1186/s13073-016-0299-7.</mixed-citation><mixed-citation xml:lang="en">Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8(1):43. https://doi.org/10.1186/s13073-016-0299-7.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Tajik N, Frech M, Schulz O, Schälter F, Lucas S, Azizov V et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020;11(1):1995. https://doi.org/10.1038/s41467020-15831-7.</mixed-citation><mixed-citation xml:lang="en">Tajik N, Frech M, Schulz O, Schälter F, Lucas S, Azizov V et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020;11(1):1995. https://doi.org/10.1038/s41467020-15831-7.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Tripathy A, Khanna S, Padhan P, Smita S, Raghav S, Gupta B. Direct recognition of LPS drive TLR4 expressing CD8+ T cell activation in patients with rheumatoid arthritis. Sci Rep. 2017;7(1):933. https://doi.org/10.1038/s41598-017-01033-7.</mixed-citation><mixed-citation xml:lang="en">Tripathy A, Khanna S, Padhan P, Smita S, Raghav S, Gupta B. Direct recognition of LPS drive TLR4 expressing CD8+ T cell activation in patients with rheumatoid arthritis. Sci Rep. 2017;7(1):933. https://doi.org/10.1038/s41598-017-01033-7.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kitamura K, Sasaki M, Matsumoto M, Shionoya H, Iida K. Protective effect of Bacteroides fragilis LPS on Escherichia coli LPS-induced inflammatory changes in human monocytic cells and in a rheumatoid arthritis mouse model. Immunol Lett. 2021;233:48–56. https://doi.org/10.1016/j.imlet.2021.03.008.</mixed-citation><mixed-citation xml:lang="en">Kitamura K, Sasaki M, Matsumoto M, Shionoya H, Iida K. Protective effect of Bacteroides fragilis LPS on Escherichia coli LPS-induced inflammatory changes in human monocytic cells and in a rheumatoid arthritis mouse model. Immunol Lett. 2021;233:48–56. https://doi.org/10.1016/j.imlet.2021.03.008.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Edilova MI, Akram A, Abdul-Sater AA. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomedj. 2021;44(2):172–182. https://doi.org/10.1016/j.bj.2020.06.010.</mixed-citation><mixed-citation xml:lang="en">Edilova MI, Akram A, Abdul-Sater AA. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomedj. 2021;44(2):172–182. https://doi.org/10.1016/j.bj.2020.06.010.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ricchiuti V, Chun KY, Yang JM, Aure MA, Gomez L, Norman GL, Mahler M. Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis. Diagnostics. 2022;12(7):1661. https://doi.org/10.3390/diagnostics12071661.</mixed-citation><mixed-citation xml:lang="en">Ricchiuti V, Chun KY, Yang JM, Aure MA, Gomez L, Norman GL, Mahler M. Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis. Diagnostics. 2022;12(7):1661. https://doi.org/10.3390/diagnostics12071661.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. https://doi.org/10.1016/j.immuni.2017.02.006.</mixed-citation><mixed-citation xml:lang="en">Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. https://doi.org/10.1016/j.immuni.2017.02.006.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130:110542. https://doi.org/10.1016/j.biopha.2020.110542.</mixed-citation><mixed-citation xml:lang="en">Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130:110542. https://doi.org/10.1016/j.biopha.2020.110542.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Petrovská N, Prajzlerová K, Vencovský J, Šenolt L, Filková M. The preclinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun Rev. 2021;20(5):102797. https://doi.org/10.1016/j.autrev.2021.102797.</mixed-citation><mixed-citation xml:lang="en">Petrovská N, Prajzlerová K, Vencovský J, Šenolt L, Filková M. The preclinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun Rev. 2021;20(5):102797. https://doi.org/10.1016/j.autrev.2021.102797.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Achudhan D, Lai YL, Lin YY, Huang YL, Tsai CH, Ho TL et al. CXCL13 promotes TNF-α synthesis in rheumatoid arthritis through activating ERK/p38 pathway and inhibiting miR-330-3p generation. Biochem Pharmacol. 2024;221:116037. https://doi.org/10.1016/j.bcp.2024.116037.</mixed-citation><mixed-citation xml:lang="en">Achudhan D, Lai YL, Lin YY, Huang YL, Tsai CH, Ho TL et al. CXCL13 promotes TNF-α synthesis in rheumatoid arthritis through activating ERK/p38 pathway and inhibiting miR-330-3p generation. Biochem Pharmacol. 2024;221:116037. https://doi.org/10.1016/j.bcp.2024.116037.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Wu T, Li Y, Liu Y, Chu CQ. Preclinical RA: How to halt its progression. Best Pract Res Clin Rheumatol. 2025;39(1):102030. https://doi.org/10.1016/j.berh.2024.102030.</mixed-citation><mixed-citation xml:lang="en">Wu T, Li Y, Liu Y, Chu CQ. Preclinical RA: How to halt its progression. Best Pract Res Clin Rheumatol. 2025;39(1):102030. https://doi.org/10.1016/j.berh.2024.102030.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. https://doi.org/10.1146/annurevmed-051113-024537.</mixed-citation><mixed-citation xml:lang="en">O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. https://doi.org/10.1146/annurevmed-051113-024537.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20(3):217–251. https://doi.org/10.1038/s41423-023-00974-6.</mixed-citation><mixed-citation xml:lang="en">Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20(3):217–251. https://doi.org/10.1038/s41423-023-00974-6.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30. https://doi.org/10.1136/annrheumdis-2019-215672.</mixed-citation><mixed-citation xml:lang="en">Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30. https://doi.org/10.1136/annrheumdis-2019-215672.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Tanner S, Dufault B, Smolik I, Meng X, Anaparti V, Hitchon C et al. A Prospective Study of the Development of Inflammatory Arthritis in the Family Members of Indigenous North American People With Rheumatoid Arthritis. Arthritis Rheumatol. 2019;71(9):1494–1503. https://doi.org/10.1002/art.40880.</mixed-citation><mixed-citation xml:lang="en">Tanner S, Dufault B, Smolik I, Meng X, Anaparti V, Hitchon C et al. A Prospective Study of the Development of Inflammatory Arthritis in the Family Members of Indigenous North American People With Rheumatoid Arthritis. Arthritis Rheumatol. 2019;71(9):1494–1503. https://doi.org/10.1002/art.40880.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, Weisman MH, Buckner JH et al. Factors associated with progression to inflammatory arthritis in firstdegree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann Rheum Dis. 2021;80(2):154–161. https://doi.org/10.1136/annrheumdis-2020-217066.</mixed-citation><mixed-citation xml:lang="en">Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, Weisman MH, Buckner JH et al. Factors associated with progression to inflammatory arthritis in firstdegree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann Rheum Dis. 2021;80(2):154–161. https://doi.org/10.1136/annrheumdis-2020-217066.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Duquenne L, Hensor EM, Wilson M, Garcia-Montoya L, Nam JL, Wu J et al. Predicting Inflammatory Arthritis in At-Risk Persons: Development of Scores for Risk Stratification. Ann Intern Med. 2023;176(8):1027–1036. https://doi.org/10.7326/M23-0272.</mixed-citation><mixed-citation xml:lang="en">Duquenne L, Hensor EM, Wilson M, Garcia-Montoya L, Nam JL, Wu J et al. Predicting Inflammatory Arthritis in At-Risk Persons: Development of Scores for Risk Stratification. Ann Intern Med. 2023;176(8):1027–1036. https://doi.org/10.7326/M23-0272.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Heutz JW, Rogier C, Niemantsverdriet E, van den Eeden SJF, de Jong PHP, Lubberts E et al. The course of cytokine and chemokine gene expression in clinically suspect arthralgia patients during progression to inflammatory arthritis. Rheumatology. 2024;63(2):563–570. https://doi.org/10.1093/rheumatology/kead238.</mixed-citation><mixed-citation xml:lang="en">Heutz JW, Rogier C, Niemantsverdriet E, van den Eeden SJF, de Jong PHP, Lubberts E et al. The course of cytokine and chemokine gene expression in clinically suspect arthralgia patients during progression to inflammatory arthritis. Rheumatology. 2024;63(2):563–570. https://doi.org/10.1093/rheumatology/kead238.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):491–496. https://doi.org/10.1136/annrheumdis-2016-209846.</mixed-citation><mixed-citation xml:lang="en">van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):491–496. https://doi.org/10.1136/annrheumdis-2016-209846.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Sahin D, Di Matteo A, Emery P. Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review. Ann Clin Biochem. 2025;62(1):3–21. https://doi.org/10.1177/00045632241285843.</mixed-citation><mixed-citation xml:lang="en">Sahin D, Di Matteo A, Emery P. Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review. Ann Clin Biochem. 2025;62(1):3–21. https://doi.org/10.1177/00045632241285843.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">van Steenbergen HW, Mangnus L, Reijnierse M, Huizinga TW, van der Helmvan Mil AH. Clinical factors, anticitrullinated peptide antibodies and MRIdetected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis. 2016;75(10):1824–1830. https://doi.org/10.1136/annrheumdis-2015-208138.</mixed-citation><mixed-citation xml:lang="en">van Steenbergen HW, Mangnus L, Reijnierse M, Huizinga TW, van der Helmvan Mil AH. Clinical factors, anticitrullinated peptide antibodies and MRIdetected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis. 2016;75(10):1824–1830. https://doi.org/10.1136/annrheumdis-2015-208138.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Zufferey P, Rebell C, Benaim C, Ziswiler HR, Dumusc A, So A. Ultrasound can be useful to predict an evolution towards rheumatoid arthritis in patients with inflammatory polyarthralgia without anticitrullinated antibodies. Joint Bone Spine. 2017;84(3):299–303. https://doi.org/10.1016/j.jbspin.2016.05.011.</mixed-citation><mixed-citation xml:lang="en">Zufferey P, Rebell C, Benaim C, Ziswiler HR, Dumusc A, So A. Ultrasound can be useful to predict an evolution towards rheumatoid arthritis in patients with inflammatory polyarthralgia without anticitrullinated antibodies. Joint Bone Spine. 2017;84(3):299–303. https://doi.org/10.1016/j.jbspin.2016.05.011.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Molina Collada J, López Gloria K, Castrejón I, Nieto-González JC, Rivera J, Montero F et al. Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development. Arthritis Res Ther. 2021;23(1):299. https://doi.org/10.1186/s13075-021-02685-7.</mixed-citation><mixed-citation xml:lang="en">Molina Collada J, López Gloria K, Castrejón I, Nieto-González JC, Rivera J, Montero F et al. Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development. Arthritis Res Ther. 2021;23(1):299. https://doi.org/10.1186/s13075-021-02685-7.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Zayat AS, Ellegaard K, Conaghan PG, Terslev L, Hensor EM, Freeston JE et al. The specificity of ultrasound-detected bone erosions for rheumatoid arthritis. Ann Rheum Dis. 2015;74(5):897–903. https://doi.org/10.1136/annrheumdis-2013-204864.</mixed-citation><mixed-citation xml:lang="en">Zayat AS, Ellegaard K, Conaghan PG, Terslev L, Hensor EM, Freeston JE et al. The specificity of ultrasound-detected bone erosions for rheumatoid arthritis. Ann Rheum Dis. 2015;74(5):897–903. https://doi.org/10.1136/annrheumdis-2013-204864.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Brunet SC, Finzel S, Engelke K, Boyd SK, Barnabe C, Manske SL. Bone changes in early inflammatory arthritis assessed with High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT): A 12-month cohort study. Joint Bone Spine. 2021;88(1):105065. https://doi.org/10.1016/j.jbspin.2020.07.014.</mixed-citation><mixed-citation xml:lang="en">Brunet SC, Finzel S, Engelke K, Boyd SK, Barnabe C, Manske SL. Bone changes in early inflammatory arthritis assessed with High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT): A 12-month cohort study. Joint Bone Spine. 2021;88(1):105065. https://doi.org/10.1016/j.jbspin.2020.07.014.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF et al. A multibiomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology. 2013;52(7):1202–1207. https://doi.org/10.1093/rheumatology/kes362.</mixed-citation><mixed-citation xml:lang="en">Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF et al. A multibiomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology. 2013;52(7):1202–1207. https://doi.org/10.1093/rheumatology/kes362.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Meznerics FA, Kemény LV, Gunther E, Bakó E, Dembrovszky F, Szabó B et al. Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis. Rheumatology. 2023;62(6):2048–2059. https://doi.org/10.1093/rheumatology/keac715.</mixed-citation><mixed-citation xml:lang="en">Meznerics FA, Kemény LV, Gunther E, Bakó E, Dembrovszky F, Szabó B et al. Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis. Rheumatology. 2023;62(6):2048–2059. https://doi.org/10.1093/rheumatology/keac715.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">AbdulRaheem Y. Unveiling the Significance and Challenges of Integrating Prevention Levels in Healthcare Practice. J Prim Care Community Health. 2023;14:21501319231186500. https://doi.org/10.1177/21501319231186500.</mixed-citation><mixed-citation xml:lang="en">AbdulRaheem Y. Unveiling the Significance and Challenges of Integrating Prevention Levels in Healthcare Practice. J Prim Care Community Health. 2023;14:21501319231186500. https://doi.org/10.1177/21501319231186500.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Gwinnutt JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, Boonen A, Cavalli G et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):48–56. https://doi.org/10.1136/annrheumdis-2021-222020.</mixed-citation><mixed-citation xml:lang="en">Gwinnutt JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, Boonen A, Cavalli G et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):48–56. https://doi.org/10.1136/annrheumdis-2021-222020.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Lin L, Zhang K, Xiong Q, Zhang J, Cai B, Huang Z et al. Gut microbiota in preclinical rheumatoid arthritis: From pathogenesis to preventing progression. J Autoimmun. 2023;141:103001. https://doi.org/10.1016/j.jaut.2023.103001.</mixed-citation><mixed-citation xml:lang="en">Lin L, Zhang K, Xiong Q, Zhang J, Cai B, Huang Z et al. Gut microbiota in preclinical rheumatoid arthritis: From pathogenesis to preventing progression. J Autoimmun. 2023;141:103001. https://doi.org/10.1016/j.jaut.2023.103001.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Cannarella LAT, Mari NL, Alcântara CC, Iryioda TMV, Costa NT, Oliveira SR et al. Mixture of probiotics reduces inflammatory biomarkers and improves the oxidative/nitrosative profile in people with rheumatoid arthritis. Nutrition. 2021;89:111282. https://doi.org/10.1016/j.nut.2021.111282.</mixed-citation><mixed-citation xml:lang="en">Cannarella LAT, Mari NL, Alcântara CC, Iryioda TMV, Costa NT, Oliveira SR et al. Mixture of probiotics reduces inflammatory biomarkers and improves the oxidative/nitrosative profile in people with rheumatoid arthritis. Nutrition. 2021;89:111282. https://doi.org/10.1016/j.nut.2021.111282.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
